1. Home
  2. BSVN vs BLSM Comparison

BSVN vs BLSM Comparison

Compare BSVN & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank7 Corp.

BSVN

Bank7 Corp.

N/A

Current Price

$58.81

Market Cap

531.3M

Sector

Finance

ML Signal

N/A

Logo BlossomHill Therapeutics Inc. Common Stock

BLSM

BlossomHill Therapeutics Inc. Common Stock

N/A

Current Price

$13.90

Market Cap

483.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BSVN
BLSM
Founded
2004
2020
Country
United States
United States
Employees
N/A
69
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
531.3M
483.4M
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
BSVN
BLSM
Price
$58.81
$13.90
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
★ $63.33
$35.40
AVG Volume (30 Days)
34.3K
★ 133.1K
Earning Date
10-15-2026
11-19-2026
Dividend Yield
★ 2.02%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 2.12
N/A
Revenue
N/A
N/A
Revenue This Year
$10.97
N/A
Revenue Next Year
$54.28
N/A
P/E Ratio
$27.98
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.29
$12.93
52 Week High
$59.96
$27.99

Technical Indicators

Market Signals
Indicator
BSVN
BLSM
Relative Strength Index (RSI) 66.57 38.13
Support Level $53.85 $12.93
Resistance Level N/A $27.99
Average True Range (ATR) 1.13 1.58
MACD 0.15 0.06
Stochastic Oscillator 81.40 18.88

Price Performance

Historical Comparison
BSVN
BLSM

About BSVN Bank7 Corp.

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

About BLSM BlossomHill Therapeutics Inc. Common Stock

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Share on Social Networks: